Roby Zomer talks through MGC’s March quarter numbers and explains to Proactive its development from the cannabinoid space into pharma and medicines.
Zomer says it is still selling cannabinoid formulations in Australia and Brazil, both of which are seeing sales grow, but also, in parallel, it is conducting clinical trials and research to create medicines.
On both these fronts, sales and in the clinic, MGC is making good progress, he adds.